All News

The study’s mixed findings on telehealth for opioid use disorder (OUD) treatment suggest a need for more individualized approaches to care.

Chris Cella, RPh, vice president of RxOwnership at McKesson, talks about how independent pharmacies can help improve their bottom line.

McKesson’s private brand of OTC health and wellness products are a great way for independent pharmacies to increase profits.

The FTC released its interim report detailing PBM practices, staggering market consolidation statistics, and the disparities between PBMs and their smaller competitors.

When used together, sodium glucose co-transporter 2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) were able to lower the risk of major adverse cardiovascular events and kidney disease by 11% and 33%, respectively.

Researchers addressed the association between semaglutide use and the risk of nonarteritic anterior ischemic optic neuropathy.

“Adding this technology to our pandemic flu toolkit enhances our ability to be nimble and quick against the circulating strains and their potential variants,” said Dawn O’Connell, assistant secretary for preparedness and response at the HSS.

Six abstracts presented at the American Diabetes Association 84th Scientific Sessions explored how different interventions or factors can impact type 2 diabetes (T2D) management.

Individuals who ate diets that aligned closer to DASH and Mediterranean guidelines had lower levels of plasminogen activator inhibitor-1 and homocysteine biomarkers.

A pilot study presented at the American Diabetes Association 84th Scientific Sessions showed that CGM technology could produce reliable results without complications in children with leukemia/lymphoma at risk for hyperglycemia.

Three posters presented at the American Diabetes Association 84th Scientific Sessions looked into the current landscape of GLP-1s.

Research presented at the American Diabetes Association 84th Scientific Sessions suggests a population approach to CGM use could be beneficial.

Jeremy Cundiff, PharmD, co-owner of Professional Pharmacy Group, joined Drug Topics to discuss Return Solutions and the company’s Rx Returns process.

Drug Topics sat down with Sandra Canally, RN, founder and CEO of The Compliance Team, and Kara Benson, PharmD, long-term care director of Lewis Drug Inc, to discuss the future of LTC pharmacy.

Catch up on important continuous glucose monitoring (CGM) news from the month of June.

In case you missed it, this week we had news about mosquito-associated health risks, the link between cannabis and COVID-19, user experience in continuous glucose monitoring, and more.

Check out a recap of important pharmacy news you might have missed this week, dispensed in small doses.

Two posters presented at the American Diabetes Association 84th Scientific Sessions looked into the impact of glucagon-like peptide-1 receptor agonists in type 1 diabetes management.

Through a test-and-treat approach, patients who test positive for HCV RNA with the Xpert HCV test and GeneXpert Xpress System can be connected to care as soon as the same health care visit.

Drug Topics has been on site at McKesson ideaShare this week! Check out this podcast to hear a few of the things we've experienced and what we've learned so far.

Check out these important FDA updates from the month of June 2024.

At McKesson ideaShare 2024, Andrea Sikora discussed artificial intelligence and how it has gradually been integrated into health care systems.

Don’t miss out on the latest pharmacy insights in the Total Pharmacy June issue.

Test your pharmacy news knowledge with our weekly quiz.

Two posters presented at the American Diabetes Association 84th Scientific Sessions looked at challenges of remote CGM in older populations and after discharge from the hospital.

“Retail pharmacy is central to our future and to our overall customer and patient experience. It enables many other things, but it has to change,” said Walgreens CEO Tim Wentworth.

The first-in-class selective dual PDE3 and PDE4 inhibitor from Verona Pharma is the first inhaled product with a novel mechanism of action approved to treat COPD in over 20 years.

At the American Diabetes Association 84th Scientific Sessions, researchers presented findings from 4 studies that investigated the impact of various new diabetes technologies on managing the condition.